Patents Examined by Jae W Lee
  • Methods of microbial oil extraction and separation
    Patent number: 11542456
    Abstract: Lipids can be extracted from a microbial biomass that constitutes at least 20% lipids by weight and has a moisture content of less than 4% by weight by applying pressure to the biomass so as to release lipids therefrom, thereby leaving a biomass of reduced lipid content; and collecting the lipids.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: January 3, 2023
    Assignee: Corbion Biotech, Inc.
    Inventors: Jon Wittenberg, Felipe Arana Rodriguez
  • Methods and compositions for delivery of CRISPR based antimicrobials
    Patent number: 11542466
    Abstract: The invention is directed to antibacterial compositions comprising bacteria modified to comprise phasmids engineered to deliver of CRISPR RNAs and methods for their use.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: January 3, 2023
    Assignee: NORTH CAROLINA STATE UNIVERSITY
    Inventors: Rodolphe Barrangou, Jan-Peter van Pijkeren
  • Mannanase variants and polynucleotides encoding same
    Patent number: 11535837
    Abstract: The present invention relates to mannanase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: December 27, 2022
    Assignee: Novozymes A/S
    Inventors: Rakhi Saikia, Naveen Shivanand Raikar, Padmavathi Balumuri, Jens Erik Nielsen
  • Modified CAS9 protein, and use thereof
    Patent number: 11530396
    Abstract: A mutant SaCas9 protein such as a protein having an amino acid sequence resulting from mutations of glutamic acid at the 782-position to lysine (E782K), leucine at the 800-position to arginine (L800R), asparagine at the 968-position to arginine (N968R), asparagine at the 985-position to alanine (N985A), arginine at the 991-position to alanine (R991A), alanine at the 1021-position to serine (A1021S), threonine at the 927-position to lysine (T927K), lysine at the 929-position to asparagine (K929N), and isoleucine at the 1017-position to phenylalanine (I1017F) in SEQ ID NO: 2 has relaxed restriction on target sequence while maintaining binding ability to guide RNA, and is useful as a tool for gene editing.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: December 20, 2022
    Assignees: THE UNIVERSITY OF TOKYO, MODALIS THERAPEUTICS CORPORATION
    Inventors: Osamu Nureki, Hiroshi Nishimasu, Hisato Hirano, Shohei Kajimoto, Tetsuya Yamagata, Yuanbo Qin, Keith M. Connolly, Iain Thompson
  • Systems and methods for modeling a protein parameter for understanding protein interactions and generating an energy map
    Patent number: 11532377
    Abstract: Systems and methods for modeling a three-dimensional protein structure are disclosed. The method includes receiving a primary amino acid sequence of a three-dimensional protein, translating the primary amino acid sequence to a first vector, determining a per-residue conformation index for each amino acid residue in the primary amino acid sequence, determining a vector set for each amino acid residue in the primary amino acid sequence, and using the per-residue interaction vector set to generate a multi-dimensional matrix for the three-dimensional protein structure. The first vector includes a unique numerical descriptor value corresponding to each amino acid residue in the primary amino acid sequence. The vector set includes a plurality per-residue interaction factors corresponding to a plurality of conformation indexes for that amino acid residue.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: December 20, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Lawrence Williams, Brian Schendt
  • Systems, methods, and compositions for correction of frameshift mutations
    Patent number: 11530425
    Abstract: The disclosure provides systems, methods, and compositions for a target specific nuclease and a blunting enzyme to correct frameshift mutations for genome editing and treatment of diseases. In some embodiments, the target specific nuclease and the blunting enzyme are combined with a guide RNA and/or a microhomology-mediated end joining (MMEJ) inhibitor.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: December 20, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Timothy Lu, Shota Nakade
  • Modified helicases
    Patent number: 11525125
    Abstract: The invention relates to a new method of characterising a target polynucleotide. The method uses a pore and a Dda helicase. The helicase controls the movement of the target polynucleotide through the pore. The invention also relates to modified Dda helicases which can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.
    Type: Grant
    Filed: June 4, 2020
    Date of Patent: December 13, 2022
    Assignee: Oxford Nanopore Technologies PLC
    Inventors: Mark John Bruce, Andrew John Heron, Ruth Moysey, Szabolcs Soeroes, Elizabeth Jayne Wallace, James White
  • Modified helicases
    Patent number: 11525126
    Abstract: The invention relates to modified helicases with reduced unbinding from polynucleotides. The helicases can be used to control the movement of polynucleotides and are particularly useful for sequencing polynucleotides.
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: December 13, 2022
    Assignee: Oxford Nanopore Technologies PLC
    Inventors: Andrew Heron, Anthony Clarke, Ruth Moysey, Elizabeth Jayne Wallace, Mark John Bruce, Lakmal Jayasinghe, Domenico Caprotti, Szabolcs Soeroes, Luke McNeill, David Antoni Alves, Rebecca Victoria Bowen, John Milton
  • Gene knockout of variant for treatment of cancer
    Patent number: 11505797
    Abstract: The disclosure provides a guide RNA (gRNA) comprising a DNA-binding domain and a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease protein-binding domain, wherein the DNA-binding domain is complementary to a target domain from a variant NRF2 gene found in a cancer cell but not in a non-cancerous cell. The disclosure also provides nucleic acid sequence encoding the gRNA. The disclosure further provides a method of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease and a guide RNA that is complementary to a target domain from a variant NRF2 gene in the subject.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: November 22, 2022
    Assignee: Christiana Care Health Services, Inc.
    Inventors: Eric Kmiec, Pawel Bialk
  • Methods and compositions for making bacteriocins and antimicrobial peptides
    Patent number: 11492651
    Abstract: Methods and compositions for making bacteriocins are described in some embodiments herein. In some embodiments, pro-polypeptide comprising the bacteriocins in the desired ratios in cis, and separated by cleavage sited can be produced by a microbial cell comprising a nucleic acid encoding the pro-polypeptide. In some embodiments microfluidic devices and methods for making specified mixtures of antimicrobial peptides and/or bacteriocins are described.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: November 8, 2022
    Assignee: Syngulon SA
    Inventor: Philippe Gabant
  • Compositions, systems, and methods for genome editing
    Patent number: 11479762
    Abstract: This disclosure provides compositions, recombinant expression constructs, and engineered systems that include a polynucleotide including or encoding a Cas12a tracrRNA, and methods for their use. The materials and methods of the disclosure are especially suited to sequence-specific genome editing of eukaryotic genomic sequences.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: October 25, 2022
    Assignee: INARI AGRICULTURE TECHNOLOGY, INC.
    Inventors: Adam Patrick Joyce, Michael Andreas Kock
  • Expression system
    Patent number: 11479776
    Abstract: A protein expression system for use in a prokaryotic host is provided, the expression system comprising: a) an expression cassette comprising a nucleic acid sequence encoding a protein of interest operably linked to a T7 RNA polymerase-dependent promoter; and b) an expression cassette comprising a nucleic acid sequence encoding T7 RNA polymerase operably linked to a host polymerase-dependent ? phage promoter and a single perfect palindrome operator sequence; wherein the expression cassette for T7 RNA polymerase is located on the chromosome of a host cell.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: October 25, 2022
    Assignee: Fujifilm Diosynth Biotechnologies UK Limited
    Inventor: Christopher Lennon
  • Increased polypeptide production yields of butyrylcholinesterase polypeptides for therapeutic use
    Patent number: 11473070
    Abstract: The presently-disclosed subject matter describes fusion proteins comprising butyrylcholinesterase (BChE) having an improved production yield and biological half-life and nucleotides encoding the same.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: October 18, 2022
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Fang Zheng
  • Flp-TAL recombinases
    Patent number: 11473066
    Abstract: The present invention provides chimeric Flp-TAL recombinases, as well as nucleic acids, and methods for the use of the chimeric Flp-TAL recombinases for site-specific alteration of a target sequence in cells.
    Type: Grant
    Filed: November 9, 2019
    Date of Patent: October 18, 2022
    Inventor: Yuri Voziyanov
  • Compositions, systems, and methods for genome editing
    Patent number: 11459551
    Abstract: This disclosure provides compositions that include a polynucleotide including or encoding a Cas12a tracrRNA, and methods for their use in sequence-specific genome editing, especially of eukaryotic genomic sequences. In particular, this disclosure provides Cas12a tracrRNA-containing compositions and methods for their use in Cas12a-mediated editing of a target sequence, wherein the editing efficiency is increased in comparison to controls lacking the Cas12a tracrRNA.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: October 4, 2022
    Assignee: INARI AGRICULTURE TECHNOLOGY, INC.
    Inventors: Adam Patrick Joyce, Michael Andreas Kock, Hannah Pham
  • Method for identifying and treating cancer
    Patent number: 11460406
    Abstract: A new system for identification and treatment against cancer, specifically the mutation or deletion of an antioncogene. An ideal candidate is a patient with family history for hereditary mutations in a known antioncogene. The first method of this system identifies the mutation of a patient's at-risk antioncogene by causing a natural fluorescence only when the specific at-risk antioncogene has mutated or deleted. The second method of this system utilizes a virus to attack and dissolve cancer cells with special markers to avoid the damage to normal cells, thereby achieving the purpose of treating cancer.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: October 4, 2022
    Inventor: Maninder Singh Matharu
  • Materials and methods for treatment of pain related disorders
    Patent number: 11459587
    Abstract: The present application provides materials and methods for treating a patient with one or more conditions associated with SCN9A whether ex vivo or in vivo. In addition, the present application provides materials and methods for editing and/or modulating the expression of SCN9A gene in a cell by genome editing.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: October 4, 2022
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Ante Sven Lundberg, Samarth Kulkarni, Lawrence Klein, Hari Kumar Padmanabhan
  • DNase H activity of Neisseria meningitidis Cas9
    Patent number: 11453864
    Abstract: Many strains of the human pathogen Neisseria meningitidis carry a compact Cas9 (NmeCas9) that can serve to limit genetic exchange via natural transformation. Cas9 orthologues (including NmeCas9) have recently been adopted for RNA-guided genome engineering and DNA binding, adding to the need to define better their activities and properties. The present invention examines DNA cleavage activities and substrate requirements of NmeCas9, including a set of unusually complex PAM recognition patterns. Unexpectedly, NmeCas9 is found able to cleave single-stranded DNA (ssDNA) targets in a manner that is RNA-guided but both PAM- and tracrRNA-independent. Beyond the requirement for guide-target pairing, this activity has no apparent sequence requirements, and the cleavage sites are measured from the 5? end of the DNA substrate's RNA-paired region.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: September 27, 2022
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Erik J. Sontheimer, Yan Zhang
  • Enhancement of CRISPR gene editing or target destruction by co-expression of heterologous DNA repair protein
    Patent number: 11453874
    Abstract: Provided are compositions, methods, and kits for improving CRISPR-based editing of DNA targets by a CRISPR-associated (Cas) enzyme. The improvement is made by combining the Cas enzyme and a CRISPR targeting RNA a heterologous DNA repair enzyme that is at least one of RecBCD, AddAB, or AdnAB. The heterologous DNA repair enzyme may have inactivated nuclease activity. The method can include using a DNA repair template to introduce one or more changes into the edited DNA. Cells that contain components of the improved CRISPR systems are included, as are kits for making such cells.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: September 27, 2022
    Assignee: The Rockefeller University
    Inventors: Luciano Marraffini, Jon McGinn, Josh Modell, Dominik Paquet
  • Multivalent particles compositions and methods of use
    Patent number: 11453705
    Abstract: Provided herein are multivalent particles and compositions of multivalent particles for blocking viral infection.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: September 27, 2022
    Assignee: ACHELOIS BIOPHARMA, INC.
    Inventors: Chang-Zheng Chen, Guoqiang Dong, Yiling Luo, Hua Zhou, Tian-Qiang Sun, Michael Chen